Immunome’s Chief Scientific Officer, Jack Higgins, executed a sale of 9,438 shares on April 2, 2026, under a pre-arranged Rule 10b5-1 trading plan, reducing his direct ownership by over 30%. The transaction, valued at approximately $204,000 based on the sale price of $21.64, reflects a strategic move for liquidity rather than a reaction to market conditions. Higgins retains a significant stake in the company, with his remaining shares valued around $480,000 at the close of trading.
This sale comes amid critical developments for Immunome, particularly the upcoming NDA submission for its lead candidate, varegacestat, following a successful Phase 3 trial. Investors should note that Higgins’s decision to sell shares does not indicate a lack of confidence in the company’s prospects, especially given the promising pipeline and expected IND submissions later this year.
For market professionals, the key takeaway is that while executive sales can raise questions, they often reflect personal financial strategies rather than company performance indicators. The focus should remain on Immunome’s upcoming milestones, which could significantly impact its stock trajectory.
Source: fool.com